Precision Medicine for Health Plans

February 6, 2019


We are pleased to offer this upcoming webinar in collaboration with Burgess and RJ Health.

Precision Medicine for Health Plans:
Managing coverage and reimbursement amidst the rapid evolution of genetic testing and targeted therapies
Wednesday, Feb. 13th
1:00-2:00 pm CT

Register here

The pace of advancement in genetics and precision medicine is staggering. Today, there are more than 75,000 genetic testing products on the market, and more than ⅓ of therapies in the development pipeline are for molecularly-defined conditions.

Health plans seeking to provide cost-effective access to high-quality healthcare must respond along several dimensions, including coverage, contracting, care management, and claims processing. The stakes are increasingly high as some therapies will cost more than $1 million per intervention and only work for a patient with a specific molecular genetic profile.

In this webinar, experts in genetic testing, drug spend, and claims payment automation will provide practical insight on the present and future of precision medicine and how leading health plans are managing the space.

Participants on the webinar will learn:
  • What areas of genetic testing are driving growth, spend, and complexity, and where are the near-term opportunities for more effective management

  • What is the state of the market for targeted therapies relative to all pharmaceuticals, and what should plans be preparing for

  • How is genetic-informed medicine changing the claims payment process and how are leading plans adapting

Who should attend:
  • Physicians and other clinicians at health plans charged with assessing clinical utility and establishing medical payment policies

  • Health plan contracting professionals faced with the challenge of contracting with genetic testing laboratories

  • Claims operations, cost management and payment integrity professionals seeking to ensure claims are paid fairly and accurately

  • Health care providers, laboratories and pharmaceutical manufacturers seeking insight into health insurers’ perspectives on precision medicine


Gillian Hooker, PhD, ScM, LCGC
VP, Clinical Development
Concert Genetics

Todd Cooperman, PharmD, MBA, RPh
Senior Vice President, Clinical Insights and Analytics
RJ Health

Jared Lorinsky
Chief Strategy Officer

Cliff Goodman, PhD (moderator)
Senior Vice President and Director, Center for Comparative Effectiveness Research
The Lewin Group


February 6, 2019


Welcome to the new Concert website! See what else is new: